Base de dados : MEDLINE
Pesquisa : Hiperplasia [Palavras]
Referências encontradas : 72231 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7224 ir para página                         

  1 / 72231 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679994
[Au] Autor:Ueki T; Nasuno M; Kaiume H; Hiroshima Y; Sumi M; Watanabe M; Inoue D; Masaki Y; Sato Y; Kojima M; Kobayashi H
[Ad] Endereço:Department of Hematology, Nagano Red Cross Hospital.
[Ti] Título:Multicentric Castleman's disease with multiple hepatic mass lesions mimicking malignant liver tumors.
[So] Source:Rinsho Ketsueki;58(6):630-636, 2017.
[Is] ISSN:0485-1439
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Multicentric Castleman's disease (MCD) is a rare, non-malignant lymphoproliferative disorder. We report a case of MCD with multiple liver masses. A 26-year-old woman presented with asymptomatic anemia and hypoalbuminemia. Laboratory tests detected high CRP levels and findings indicative of polyclonal gammopathy. Abdominal CT revealed multiple hepatic large masses (≤10 cm) and partial calcification in the right lobe. Multiple enlarged lymph nodes were also identified in the cardiophrenic angle and porta hepatis. We suspected hepatic malignancy, but pathological examinations of the liver and lymph nodes demonstrated polyclonal plasma cell infiltration and fibrosis. IL-6 staining was positive for plasma cell infiltration of lymph nodes. A few plasma cells were positive for IgG4, and tests for HIV and HHV-8 were negative. Serum IL-6 and plasma VEGF levels were both elevated (45 and 536 pg/ml, respectively). The patient was diagnosed with plasma cell type MCD. We started treatment with PSL 1 mg/kg/day, which led to improvement of anemia, hypoalbuminemia, and high CRP levels. Marginal regression of liver masses was also observed. At the last follow-up, the patient had been progression-free for 18 months. To our knowledge, this is the first report of a plasma cell type MCD with liver masses.
[Mh] Termos MeSH primário: Diagnóstico Diferencial
Hiperplasia do Linfonodo Gigante/diagnóstico
Neoplasias Hepáticas/diagnóstico
Fígado/patologia
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios/uso terapêutico
Biópsia
Feminino
Hiperplasia do Linfonodo Gigante/quimioterapia
Hiperplasia do Linfonodo Gigante/patologia
Humanos
Imagem Multimodal
Prednisolona/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170706
[St] Status:MEDLINE
[do] DOI:10.11406/rinketsu.58.630


  2 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457310
[Au] Autor:Lubbers SM; Japing WJ
[Ad] Endereço:Department of Ophthalmology, University Medical Center Groningen, Groningen, Netherlands. Electronic address: s.m.lubbers01@umcg.nl.
[Ti] Título:Unilateral choroidal detachment following the use of tamsulosin.
[So] Source:Can J Ophthalmol;52(2):e75-e77, 2017 Apr.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças da Coroide/induzido quimicamente
Corioide/patologia
Sulfonamidas/efeitos adversos
Acuidade Visual
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/efeitos adversos
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Corioide/efeitos de drogas
Doenças da Coroide/diagnóstico
Doenças da Coroide/fisiopatologia
Humanos
Masculino
Microscopia Acústica
Hiperplasia Prostática/quimioterapia
Sulfonamidas/uso terapêutico
Tomografia de Coerência Óptica/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Sulfonamides); G3P28OML5I (tamsulosin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  3 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28143431
[Au] Autor:Vierkant RA; Degnim AC; Radisky DC; Visscher DW; Heinzen EP; Frank RD; Winham SJ; Frost MH; Scott CG; Jensen MR; Ghosh K; Manduca A; Brandt KR; Whaley DH; Hartmann LC; Vachon CM
[Ad] Endereço:Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
[Ti] Título:Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.
[So] Source:BMC Cancer;17(1):84, 2017 Jan 31.
[Is] ISSN:1471-2407
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Atypical hyperplasia (AH) and mammographic breast density (MBD) are established risk factors for breast cancer (BC), but their joint contributions are not well understood. We examine associations of MBD and BC by histologic impression, including AH, in a subcohort of women from the Mayo Clinic Benign Breast Disease Cohort. METHODS: Women with a diagnosis of BBD and mammogram between 1985 and 2001 were eligible. Histologic impression was assessed via pathology review and coded as non-proliferative disease (NP), proliferative disease without atypia (PDWA) and AH. MBD was assessed clinically using parenchymal pattern (PP) or BI-RADS criteria and categorized as low, moderate or high. Percent density (PD) was also available for a subset of women. BC and clinical information were obtained by questionnaires, medical records and the Mayo Clinic Tumor Registry. Women were followed from date of benign biopsy to BC, death or last contact. Standardized incidence ratios (SIRs) compared the observed number of BCs to expected counts. Cox regression estimated multivariate-adjusted MBD hazard ratios. RESULTS: Of the 6271 women included in the study, 1132 (18.0%) had low MBD, 2921 (46.6%) had moderate MBD, and 2218 (35.4%) had high MBD. A total of 3532 women (56.3%) had NP, 2269 (36.2%) had PDWA and 470 (7.5%) had AH. Over a median follow-up of 14.3 years, 528 BCs were observed. The association of MBD and BC risk differed by histologic impression (p-interaction = 0.03), such that there was a strong MBD and BC association among NP (p < 0.001) but non-significant associations for PDWA (p = 0.27) and AH (p = 0.96). MBD and BC associations for AH women were not significant within subsets defined by type of MBD measure (PP vs. BI-RADS), age at biopsy, number of foci of AH, type of AH (lobular vs. ductal) and body mass index, and after adjustment for potential confounding variables. Women with atypia who also had high PD (>50%) demonstrated marginal evidence of increased BC risk (SIR 4.98), but results were not statistically significant. CONCLUSION: We found no evidence of an association between MBD and subsequent BC risk in women with AH.
[Mh] Termos MeSH primário: Densidade da Mama/fisiologia
Neoplasias da Mama/patologia
Mama/patologia
Hiperplasia/patologia
[Mh] Termos MeSH secundário: Biópsia/métodos
Estudos de Coortes
Feminino
Humanos
Mamografia/métodos
Meia-Idade
Lesões Pré-Cancerosas/patologia
Medição de Risco
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170201
[St] Status:MEDLINE
[do] DOI:10.1186/s12885-017-3082-2


  4 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28044238
[Au] Autor:Cindolo L; Ruggera L; Destefanis P; Dadone C; Ferrari G
[Ad] Endereço:Department of Urology, ASL Abruzzo 02, Chieti, Italy. lucacindolo@virgilio.it.
[Ti] Título:Vaporize, anatomically vaporize or enucleate the prostate? The flexible use of the GreenLight laser.
[So] Source:Int Urol Nephrol;49(3):405-411, 2017 Mar.
[Is] ISSN:1573-2584
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:PURPOSES: GreenLight laser has gained increasing acceptance as a less invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH/LUTS). Three surgical options were developed: standard photovaporization (PVP), anatomical PVP and GreenLight enucleation of prostate (GreenLEP); however, literature lacks a direct comparison among the procedures. Aim of the present study is to compare the three techniques in a multicentre series of patients. METHODS: Data were collected from consecutive patients with indication to surgical management of BPH/LUTS in five institutions. Patients underwent standard PVP, anatomical PVP or GreenLEP according to surgeon preferences. Standard parameters associated with transurethral prostate surgery were documented prior surgery and during the follow-up. Patients' perception of improvement was measured using a single-item scale. Early (within first 30 post-operative days) and delayed post-operative complications were recorded. Descriptive statistics, univariate and multivariate analysis were used. RESULTS: We evaluate 367 consecutive patients (mean age 69.1 years). Median prostate size and PSA were 68 ml (IQR 50-90) and 2.8 ng/ml (IQR 1.7-4.3), respectively. The median operative time and applied energy were 60 min (IQR 45-75) and 250 kJ (IQR 160-364). Catheterization time and median post-operative stay were 1 and 2 days. No patient was transfused. The overall median Q values increased for 8-19 ml/s (p < 0.05), median International Prostate Symptoms Score decreased from 24 to 7 (p < 0.05). A total of 7.4% urinary retention, 33.4% bothersome storage symptoms, 2.5% short-term stress incontinence were recorded. Three heart attacks, one pulmonary embolism and one death occurred. Prostate volume was a predictive factor for post-operative storage symptoms (p = 0.049). Nine percentage of patients experienced long-term complications (4, 0.9 and 0.9% of urethral stricture, bladder neck contracture and prostatic fossa sclerosis, respectively) with 2.5% of long-term stress urinary incontinence (conservatively managed). The reintervention rate was 6%. Late complications were associated at univariate analysis with pharmacological therapy (combination therapy vs. alpha blockers alone vs. none: p value = 0.042) and with the surgical approach (standard PVP vs. anatomical PVP vs. GreenLEP p value = 0.011). The patients' perception of satisfaction was 68% "greatly improved", 27% "improved", 4% "not changed" and 1% "worsened" with no differences between techniques. CONCLUSION: The availability of three different GreenLight laser techniques allows surgeons with different skills to safety use this technology that remains effective with high patient satisfaction. Anatomical vaporization seems to guarantee the best balance between functional outcomes, surgical procedures and complications.
[Mh] Termos MeSH primário: Lasers de Estado Sólido/uso terapêutico
Sintomas do Trato Urinário Inferior/cirurgia
Próstata/patologia
Hiperplasia Prostática/cirurgia
[Mh] Termos MeSH secundário: Idoso
Humanos
Terapia a Laser/efeitos adversos
Terapia a Laser/métodos
Lasers de Estado Sólido/efeitos adversos
Tempo de Internação
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Meia-Idade
Duração da Cirurgia
Tamanho do Órgão
Satisfação do Paciente
Complicações Pós-Operatórias/etiologia
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Reoperação
Estudos Retrospectivos
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE
[do] DOI:10.1007/s11255-016-1494-6


  5 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27987130
[Au] Autor:Liu Q; Zhu Y; Liu J; Qi J; Kang J
[Ad] Endereço:Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China.
[Ti] Título:Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
[So] Source:Int Urol Nephrol;49(3):399-404, 2017 Mar.
[Is] ISSN:1573-2584
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Intravesical prostatic protrusion (IPP) is a type of benign prostatic hyperplasia (BPH) adenoma, and it plays a critical role in the pathogenesis of bladder outlet obstruction in patients with lower urinary tract syndromes (LUTS/BPH). AIMS: The goal of this study was to investigate the effect of a combination therapy with finasteride and doxazosin on IPP in BPU/LUTS patients. METHODS: A total of 322 BPH patients with enlarged prostatic volume as well as moderate to severe symptom scores were enrolled and divided into four groups according to the degree of IPP (IPP > 10 mm, 5-10 mm, <5 mm and no IPP) in this study. Aggravated International Prostatic Symptom Score (IPSS), acute urinary retention or relevant urinary complications were considered as failure of the therapy. The degrees of IPP were recorded before and after 6 months of treatment. Student's t test and χ were performed between the baseline and endpoint of the therapy. RESULTS: The results showed that the total prostate volume (TPV) and transition zone volume (TZV) of the prostate decreased significantly after 6-month combination therapy (P < 0.05), while no significant changes in IPP were observed at that point (P > 0.05). Failure rates of the medication differed significantly among the four groups. CONCLUSIONS: The study indicated that the combination therapy using finasteride and doxazosin could not reduce the degree of IPP. LUTS/BPH patients with IPP which contributes to the failure of medication tend to have a higher risk of progression.
[Mh] Termos MeSH primário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Doxazossina/uso terapêutico
Finasterida/uso terapêutico
Próstata/patologia
Hiperplasia Prostática/diagnóstico por imagem
Hiperplasia Prostática/quimioterapia
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Quimioterapia Combinada
Humanos
Masculino
Meia-Idade
Tamanho do Órgão
Próstata/diagnóstico por imagem
Antígeno Prostático Específico/sangue
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Prostatismo/quimioterapia
Prostatismo/etiologia
Falha de Tratamento
Ultrassonografia
Bexiga Urinária/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Urological Agents); 57GNO57U7G (Finasteride); EC 3.4.21.77 (Prostate-Specific Antigen); NW1291F1W8 (Doxazosin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1007/s11255-016-1478-6


  6 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28394533
[Au] Autor:Enikeev DV; Glybochko PV; Alyaev YG; Rapoport LM; Vinarov AZ; Enikeev ME; Sorokin NI; Spivak LG; Sukhanov RB; Dymov AM; Khamraev OK; Taratkin MS; Davydov DS; Vinnichenko VA
[Ad] Endereço:Urology Clinic, I.M. Sechenov First MSMU, Moscow, Russia.
[Ti] Título:[Current laser technologies for the surgical treatment of prostatic hyperplasia].
[So] Source:Urologiia;(1):108-113, 2017 Apr.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The first medical application of lasers dates back to the mid-60s of the XX century. Since then, laser systems have undergone significant changes. No longer a science fiction, lasers are used in many medical fields as an indispensable tool in the hands of the modern physician. The article outlines advances in laser techniques (from the idea of laser radiation to the modern laser systems used as effective surgical tools). We also present our experience in using laser surgical techniques in treating patients with prostatic hyperplasia.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Hiperplasia Prostática/cirurgia
[Mh] Termos MeSH secundário: Endoscopia
Humanos
Terapia a Laser/instrumentação
Lasers de Estado Sólido/uso terapêutico
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  7 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28394531
[Au] Autor:Gadzhieva ZK; Kazilov YB
[Ad] Endereço:I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[New opportunities to treat combined luts in patients with benign prostatic hyperplasia premises and advantages].
[So] Source:Urologiia;(1):95-102, 2017 Apr.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:This paper provides an overview of studies on the prevalence, pathogenesis and management of combined lower urinary tract symptoms (LUTs) in men. The authors emphasize the role of urodynamic studies in the diagnosis of LUTs in the pre- and postoperative period aimed at the early detection of functional lower urinary tract disorders and selection of the appropriate medical treatment.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/quimioterapia
Hiperplasia Prostática/complicações
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Quimioterapia Combinada
Humanos
Sintomas do Trato Urinário Inferior/diagnóstico
Sintomas do Trato Urinário Inferior/epidemiologia
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Antagonistas Muscarínicos/uso terapêutico
Hiperplasia Prostática/cirurgia
Urodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Muscarinic Antagonists)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  8 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28394524
[Au] Autor:Neimark AI; Tachalov MA; Neimark BA; Torbik DV; Arzamastsev DD
[Ad] Endereço:Department of Specialized Surgery in Urology, Traumatology and Ophthalmology, Altai State Medical University, Barnaul, Russia.
[Ti] Título:[X-ray-guided endovascular surgery in patients with benign prostatic hyperplasia and prostate cancer].
[So] Source:Urologiia;(1):54-60, 2017 Apr.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To evaluate the efficacy and safety of superselective embolization and chemoembolization of the prostatic artery as an independent method of treating prostate cancer and BPH. MATERIALS AND METHODS: From 2004 to 2015, 116 patients with BPH (mean age 73.2+/-5.2 years) underwent prostatic artery embolization. Mean prostate volume ranged from 55 to 296 cc3. From 2011 to 2015, 37 patients with prostate cancer (mean age 72.3+/-2.06 years) were treated with X-ray-guided endovascular chemoembolization. All patients had confirmed PCa, of whom 7 had stage T2a and 30 stage T2c disease. PSA ranged from 0.8 to17 ng/ml (mean 13.1+/-3.9). Prostate volume ranged from 61 to 93 cc3 (mean 69.4+/-9.3). The follow-up ranged from 8 to 42 months. RESULTS: Prostatic artery embolization in BPH patients resulted in a significant reduction in IPSS symptom score and increase in Qmax. The volume of prostate and nodular mass decreased on average by 53% and 47%, respectively, maximum by 82%. Chemoembolization was effective in 31 (83.7%) patients. An objective response was achieved in reducing the PSA level and prostate volume measured by TRUS, and improved urination. The median PSA at 6 months was - 3.4 +/- 0.02 ng/ml. In all patients, chemoembolization resulted in a marked reduction in the prostate volume. The greatest decrease in the prostate volume was observed at 6 months after treatment. Chemoembolization led to a marked improvement in the quality of urination confirmed by uroflowmetry and IPSS symptom scores. At 12 months, 16 patients with prostate cancer underwent the follow-up biopsy. In 12 cases pathology showed fibrosis and epithelial degeneration without signs of atypia and in 2 cases curative pathomorphosis was observed. Chemoembolization was well tolerated and did not cause any significant complications. CONCLUSION: Embolization techniques for BPH and chemoembolization for localized PCa showed good effectiveness and safety in patients who had medical contraindications to traditional treatments.
[Mh] Termos MeSH primário: Hiperplasia Prostática/cirurgia
[Mh] Termos MeSH secundário: Idoso
Embolização Terapêutica
Procedimentos Endovasculares
Humanos
Masculino
Próstata/irrigação sanguínea
Hiperplasia Prostática/diagnóstico por imagem
Radiografia
Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  9 / 72231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28394516
[Au] Autor:Atamanova EA; Andryukhin MI; Vasilenko IA; Makarov OV
[Ad] Endereço:Peoples Friendship University of Russia, Department of Urology and Surgical Nephrology with the Course of Oncourology, Moscow, Russia.
[Ti] Título:[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
[So] Source:Urologiia;(1):5-11, 2017 Apr.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To improve the results of surgical treatment of benign prostatic hyperplasia. MATERIALS AND METHODS: The study investigated the effectiveness of a comprehensive preoperative preparation of patients with benign prostatic hyperplasia. The clinical efficacy of traditional methods of preoperative preparation (compression bandaging of the lower extremities during surgery and in the postoperative period and Fraxiparine at a prophylactic dose) was compared with the same preoperative protocol used in combination with intravenous laser blood irradiation. The explored parameters included changes in clinical and laboratory coagulation indices and prostatic blood flow measured by Doppler sonography. The real time visualization was used to assess the effect of intravenous laser irradiation of blood on the morphofunctional state of platelets. CONCLUSION: The study findings showed a high effectiveness of intravenous laser blood irradiation in preoperative preparation of patients with benign prostatic hyperplasia. It was found to reduce the incidence of thrombotic events by 6% and hemorrhagic complications by 4.9% (p<0.05).
[Mh] Termos MeSH primário: Hemorragia/prevenção & controle
Complicações Pós-Operatórias/prevenção & controle
Cuidados Pré-Operatórios/métodos
Hiperplasia Prostática/cirurgia
Trombose/prevenção & controle
[Mh] Termos MeSH secundário: Fibrinolíticos/uso terapêutico
Hemorragia/etiologia
Humanos
Terapia com Luz de Baixa Intensidade
Masculino
Nadroparina/uso terapêutico
Prostatectomia
Trombose/etiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 0 (Nadroparin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE


  10 / 72231 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28135625
[Au] Autor:Chen J; Zhang J; Yang J; Xu L; Hu Q; Xu C; Yang S; Jiang H
[Ad] Endereço:Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
[Ti] Título:Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
[So] Source:Atherosclerosis;257:152-163, 2017 Feb.
[Is] ISSN:1879-1484
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Deregulation of histone demethylase KDM3a, an important regulator for H3K9 methylation, is correlated with obesity and abnormal metabolism in rodent models. However, the function of KDM3a in vascular remodeling under diabetic condition is unknown. METHODS: Adenoviruses expressing KDM3a and lentiviruses expressing KDM3a-targeting siRNA were generated to study the role of KDM3a both in vivo and in vitro. The carotid artery balloon injury model was established in diabetic SD rats to evaluate the significance of KDM3a in vascular injury. RESULTS: Diabetic vessels were associated with sustained loss of histone H3 lysine 9 di-methylation (H3K9me2) and elevation of KDM3a. This phenomenon was induced by high glucose (HG) and was persistently present even after removal from diabetic condition and high glucose in vascular smooth muscle cells (VSMCs). After 28-day balloon injury, KDM3a overexpression accelerated while KDM3a knockdown reduced neointima formation, following vascular injury in diabetic rats without glucose control. Microarray analysis revealed KDM3a altered the expression of vascular remodeling genes; particularly, it mediated the Rho/ROCK and AngII/AGTR1 pathways. In the in vivo study, HG and Ang II-stimulated proliferation and migration of VSMCs were enhanced by KDM3a overexpression, whereas markedly prevented by KDM3a knockdown. KDM3a regulated the transcription of AGTR1 and ROCK2 via controlling H3K9me2 in the proximal promoter regions. CONCLUSIONS: Histone demethylase KDM3a promotes vascular neointimal hyperplasia in diabetic rats via AGTR1 and ROCK2 signaling pathways. Targeting KDM3a might represent a promising therapeutic approach for the prevention of coronary artery disease with diabetes.
[Mh] Termos MeSH primário: Lesões das Artérias Carótidas/enzimologia
Proliferação de Células
Diabetes Mellitus Experimental/enzimologia
Histona Desmetilases/metabolismo
Histona Desmetilases com o Domínio Jumonji/metabolismo
Músculo Liso Vascular/enzimologia
Miócitos de Músculo Liso/enzimologia
Neointima
[Mh] Termos MeSH secundário: Animais
Artérias Carótidas/enzimologia
Artérias Carótidas/patologia
Lesões das Artérias Carótidas/genética
Lesões das Artérias Carótidas/patologia
Diabetes Mellitus Experimental/genética
Diabetes Mellitus Experimental/patologia
Regulação da Expressão Gênica
Células HEK293
Histona Desmetilases/genética
Histonas/metabolismo
Humanos
Hiperplasia
Histona Desmetilases com o Domínio Jumonji/genética
Masculino
Metilação
Músculo Liso Vascular/patologia
Miócitos de Músculo Liso/patologia
Regiões Promotoras Genéticas
Interferência de RNA
Ratos Sprague-Dawley
Receptor Tipo 1 de Angiotensina/genética
Receptor Tipo 1 de Angiotensina/metabolismo
Transdução de Sinal
Fatores de Tempo
Transcrição Genética
Transfecção
Quinases Associadas a rho/genética
Quinases Associadas a rho/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histones); 0 (Receptor, Angiotensin, Type 1); EC 1.14.11.- (Histone Demethylases); EC 1.14.11.- (Jumonji Domain-Containing Histone Demethylases); EC 2.7.11.1 (ROCK2 protein, human); EC 2.7.11.1 (rho-Associated Kinases); EC 3.5.1.98 (histone demethylase KDM3a, rat)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170130
[St] Status:MEDLINE



página 1 de 7224 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde